急性间歇性紫质症市场规模、份额、成长分析（按诊断、按治疗、按最终用户、按地区）- 2025 年至 2032 年产业预测

急性间歇性紫质症市场规模预计在 2023 年达到 43.2 亿美元，到 2032 年将达到 56.9 亿美元，预计在预测期内（2025-2032 年）的复合年增长率为 3.1%。

由于人们认识的提高、诊断方法的进步以及创新治疗方法的发展，急性间歇性紫质症(AIP) 市场正在经历显着成长。这种影响血红素合成的罕见遗传性疾病是医疗领域的一股驱动力。基因检测等诊断能力的提高可以早期准确地识别 AIP 病例。此外，製药业正专注于新治疗方法的研究和开发，而改善病患教育有助于有效控制症状。儘管取得了这些进展，但诊断不足和治疗选择有限等挑战仍然存在。医学专家、研究人员和製药公司之间的合作方式对于应对 AIP 市场的复杂性和改善患者的治疗效果至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

急性间歇性紫质症市场规模（依诊断及复合年增长率）（2025-2032）

• 市场概览
• 血液检查
• 尿液检查
• DNA检测
• 血清检测

急性间歇性紫质症市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 促性腺激素分泌释放激素类似物
• 预防性注射血红素

急性间歇性紫质症市场规模（依最终用户划分）及复合年增长率（2025-2032）

• 市场概览
• 医院
• 诊所
• 研究中心

急性间歇性紫质症市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • Alnylam Pharmaceuticals（美国）
    • Recordati SpA（义大利）
    • 赛诺菲公司（法国）
    • BioMarin製药公司（美国）
    • 西门子医疗股份公司（德国）
    • F. Hoffmann-La Roche Ltd（瑞士）
    • 武田药品工业株式会社（日本）
    • 益普生製药（法国）
    • Clinuvel Pharmaceuticals Ltd（澳洲）
    • Quest Diagnostics（美国）
    • 梅奥诊所实验室（美国）
    • Bachem Holding AG（瑞士）
    • Grifols, SA（西班牙）
    • 辉凌製药（瑞士）
    • 太阳製药工业有限公司（印度）
    • Moderna公司（美国）
    • Dicerna Pharmaceuticals, Inc.（美国）
    • Zambon SpA（义大利）
    • Luitpold Pharmaceuticals, Inc.（美国）
    • Vifor Pharma（瑞士）

结论和建议

Acute Intermittent Porphyria Market size was valued at USD 4.32 billion in 2023 and is poised to grow from USD 4.45 billion in 2024 to USD 5.69 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth due to increased awareness, advancements in diagnostics, and the development of innovative treatment options. This rare genetic disorder, which affects heme synthesis, is gaining traction in the healthcare sector. Enhanced diagnostic capabilities, such as genetic testing, have led to earlier and more accurate identification of AIP cases. Furthermore, the pharmaceutical industry is focusing on research and development of novel therapies, while improved patient education is helping to manage symptoms effectively. Despite these advancements, challenges such as underdiagnosis and limited treatment options persist. A collaborative approach among healthcare professionals, researchers, and pharmaceutical companies is essential to navigate the complexities of the AIP market and improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The increasing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling quicker intervention and more effective management. Furthermore, the development of innovative treatment options, including hematin infusions and novel RNA interference therapies such as givosiran, presents robust strategies for managing acute attacks and providing sustained symptom control. This combination of enhanced detection and evolving therapeutic alternatives is driving the growth of the AIP market, ultimately improving patient outcomes and quality of life for those affected by this rare genetic disorder.

Restraints in the Acute Intermittent Porphyria Market

A significant constraint in the Acute Intermittent Porphyria (AIP) market is the challenge of underdiagnosis, which stems from the condition's rarity and the intricate nature of its symptoms. This complexity often results in delays or even oversight in recognizing those affected by AIP. Furthermore, the limited availability of treatment options compounds this issue, as current therapies primarily focus on managing symptoms rather than providing a definitive cure. This scenario effectively hampers the market's growth potential, as both diagnosis and treatment face considerable hurdles that can impede timely and effective patient care.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by advancements in genetic testing technologies that enhance the accuracy and timeliness of diagnoses. This trend is complemented by the emergence of innovative treatments such as RNA interference (RNAi) therapies, notably givosiran, which offer a targeted approach to address the genetic underpinnings of AIP. As these testing methodologies and cutting-edge treatments gain traction, they are likely to improve patient outcomes and foster more personalized management strategies. This convergence of diagnostics and therapeutics is expected to propel market expansion and stimulate interest from pharmaceutical companies and investors alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations